Status:
COMPLETED
Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries
Lead Sponsor:
AstraZeneca
Conditions:
COVID-19
Eligibility:
All Genders
Brief Summary
Study on Clinical Use of EVUSHELD (AZD7442) as Pre-exposure Prophylaxis in the Real-world Setting - A Multi-Centre Observational Prospective Study to Determine the Utilization and Clinical Outcomes of...
Detailed Description
Study on Clinical use of EVUSHELD (AZD7442) as pre-exposure prophylaxis in the Real-world Setting Observational Prospective Study to determine the utilization and Clinical Outcomes of EVUSHELD in GCC....
Eligibility Criteria
Inclusion
- Individuals receiving their first dose of AZD7442 for the prevention of SARS-CoV-2 infection within the 30 days prior to study enrolment.
- The ability or willingness to sign informed consent/assent forms
Exclusion
- Patients currently participating in interventional clinical trials of SARS-CoV-2 vaccines, other SARS-CoV-2 prophylactic interventions, or COVID-19 treatments.
- Patients with an ongoing COVID-19 infection at the time of AZD7442 administration as judged by the study physician.
Key Trial Info
Start Date :
June 23 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 27 2024
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT05315323
Start Date
June 23 2022
End Date
June 27 2024
Last Update
June 29 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Abu Dhabi, United Arab Emirates
2
Research Site
Dubai, United Arab Emirates